Welcome to our dedicated page for Beam Therapeutics SEC filings (Ticker: BEAM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Beam Therapeutics Inc. (BEAM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed biotechnology issuer. Beam files reports and current reports with the U.S. Securities and Exchange Commission that describe its financial condition, clinical development progress and material corporate events related to its precision genetic medicines platform.
Investors can review Form 8-K filings in which Beam reports items such as quarterly financial results and significant transactions. For example, the company has used Form 8-K to furnish press releases announcing results for quarters ended June 30 and September 30, and to disclose an Agreement and Plan of Merger under which it acquired an early-stage life sciences company in exchange for upfront shares and potential milestone-based consideration.
In addition to 8-Ks, Beam’s periodic reports on Form 10-K and Form 10-Q (accessible via EDGAR and summarized on this page when available) typically include information on its base editing platform, programs such as risto-cel (formerly BEAM-101), BEAM-302 and BEAM-301, risk factors, liquidity and capital resources. These filings also describe regulatory designations, clinical trial status and collaboration arrangements that are important for understanding the company’s development-stage business.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify disclosures on topics like clinical milestones, cash runway, collaboration agreements and equity issuances. Real-time updates from EDGAR ensure that new Beam filings, including any future Forms 4 reporting insider transactions or proxy statements on executive compensation and governance, are surfaced promptly.
By combining official SEC documents with AI-generated overviews, this page helps investors and researchers analyze Beam’s regulatory history, financial reporting and material events that influence the BEAM stock narrative.
Beam Therapeutics CEO John M. Evans reported several stock and option transactions. On January 29–30, 2026, he exercised stock options with a $0.67 exercise price, acquiring 19,336, 5,664 and 25,000 shares of common stock. On the same dates, he sold blocks of 16,333, 8,667, 22,094 and 2,906 shares at weighted average prices ranging from about $27.87 to $29.92, all under a Rule 10b5‑1 trading plan adopted on May 16, 2025. After these trades, he directly beneficially owned 986,667 common shares and indirectly held 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust. On January 31, 2026, he was also granted a new stock option for 180,000 shares at an exercise price of $27.62, vesting in equal monthly installments over 48 months, subject to continued service.
Beam Therapeutics Inc. reported that its Chief Medical Officer, Simon Amy, received a new stock option grant. On January 31, 2026, Simon Amy was awarded a stock option to buy 88,500 shares of Beam common stock at an exercise price of $27.62 per share, expiring on January 31, 2036. The option was granted at no cost to receive it and will vest in equal monthly installments over 48 months, contingent on continued service with Beam Therapeutics through each vesting date.
John M Evans has filed a notice to sell 25,000 shares of BEAM common stock on the NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services. The planned sale has an aggregate market value of $708,947.50, with 101,474,944 shares outstanding.
The 25,000 shares to be sold were acquired on January 30, 2026 via a stock option exercise from the issuer, paid in cash on the same date. During the past three months, Evans also sold 25,000 common shares on January 29, 2026 for gross proceeds of $734,582.50.
Beam Therapeutics filed a Form 144 notice for a planned insider stock sale. The filing covers a proposed sale of 25,000 shares of common stock with an aggregate market value of $734,582.50 through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/29/2026.
The 25,000 shares were acquired on 01/29/2026 by exercising stock options directly from the issuer and paid for in cash. Shares of Beam Therapeutics outstanding were 101,474,944 at the time referenced, providing a baseline for the size of this planned sale.
Bethany J. Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics Inc., sold 6,198 shares of common stock on January 22, 2026 at a weighted average price of $35.0005 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 19, 2025. After this transaction, she directly owns 34,813 shares of Beam Therapeutics common stock.
Beam Therapeutics Chief Legal Officer Christine Bellon sold 1,371 shares of Beam Therapeutics common stock at $34 per share on January 22, 2026, under a Rule 10b5-1 trading plan. After this planned sale, she directly beneficially owned 95,667 shares of the company’s common stock. The trading plan was adopted by the reporting person on September 16, 2025, indicating the sale was executed pursuant to a pre-arranged schedule rather than a discretionary, same-day decision.
Beam Therapeutics insider plans additional stock sale under Rule 144. A holder intends to sell 1,371 shares of Beam common stock through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of
The shares to be sold were acquired as restricted stock from the issuer on three dates in
Beam Therapeutics Inc. senior vice president of finance and treasurer Bethany J. Cavanagh reported a planned sale of company stock. On January 20, 2026, she sold 3,034 shares of Common Stock of Beam Therapeutics at a price of $30.12 per share, leaving her with 41,011 shares beneficially owned directly after the transaction. The sale was carried out under a Rule 10b5-1 trading plan that she adopted on September 19, 2025, which means the trades were pre-arranged according to preset instructions rather than made at her discretion on the trade date.
Beam Therapeutics Inc. Chief Legal Officer Christine Bellon reported sales of company common stock in open-market transactions on January 15, 2026, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 16, 2025.
She sold blocks of Beam common stock at weighted-average prices of $33.6219, $34.7182 and $35.3988, with each price reflecting multiple trades within disclosed ranges. Following these sales, Bellon directly beneficially owned 97,038 shares of Beam common stock.
Christine Bellon filed a Rule 144 notice for the planned sale of 18,629 shares of BEAM common stock through Morgan Stanley Smith Barney LLC on NASDAQ. The shares to be sold have an aggregate market value of $644,830.69, while 101,474,944 shares of common stock are reported as outstanding. The filing lists these shares as common stock awards acquired as restricted stock from the issuer between March 31, 2022 and March 31, 2024. It also notes that in the previous three months, Bellon sold 1,254 common shares on January 2, 2026 for gross proceeds of $33,978.85. The approximate date for the new sale is January 15, 2026.